ODYSSEY MONO: Effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks

Future Cardiology

Volumn 11, Issue 1, 2015, Pages 27-37

  Roth, Eli M ^a   McKenney, James M ^b  

^a UNIVERSITY OF CINCINNATI   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Alirocumab; ezetimibe; hypercholesterolemia; LDL C; PCSK9; SAR236553 REGN727

Indexed keywords

ALIROCUMAB; EZETIMIBE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; AZETIDINE DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTHRALGIA; BACKACHE; CHOLESTEROL BLOOD LEVEL; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; INFLUENZA; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MUSCULOSKELETAL DISEASE; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHINOPHARYNGITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; SUBCUTANEOUS DRUG ADMINISTRATION;

ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED;

EID: 84921662920     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.14.82     Document Type: Review

References (21)

1. National Cholesterol Education Program, National Heart, Lung and Blood Institute, NIH. Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. NIH Publication No. 02-5215. www.nhlbi.nih.gov (2002).
2. WHO. Leading causes of death. www.who.int
3. Stone NJ, Robinson J, Lichtenstein AH et al. Cardiovascular risk in adults: a report of the American College of Cardiology/American 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129(25 Suppl. 2), S1-S45 (2014).
4. Anderson TJ, Gregoire J, Hegele RA et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can. J. Cardiol. 29(2), 151-167 (2013).
5. Catapano AL, Reiner Z, De Backer G et al. ESC/EAS guidelines for the management of dyslipidaemias the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 217(1), 3-46 (2011).
6. Waters DD, Brotons C, Chiang CW et al.; Lipid Treatment Assessment Project 2 Investigators. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation 120, 28-34 (2009).
7. Nordestgaard BG, Chapman MJ, Humphries SE et al.; European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur. Heart J. 34(45), 3478a-3490a (2013).
8. Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderatemuscular symptomswith high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc. Drugs Ther. 19, 403-414 (2005).
9. Abifadel M, Varret M, Rabes JP et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34, 154-6 (2003).
10. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354, 1264-72 (2006).
11. Goldstein JL, Brown MS. The LDL receptor. Arterioscler. Thromb. Vasc. Biol. 29, 431-438 (2009).
12. Stein EA, Swergold GD. Potential of proprotein convertase subtilisin/kexin type 9 based therapeutics. Curr. Atheroscler. Rep. 15, 310 (2013).
13. Stein EA, Mellis S, Yancopoulos GD et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N. Engl. J. Med. 366, 1108-1118 (2012).
14. McKenney JM, Koren MJ, Kereiakes DJ et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J. Am. Coll. Cardiol. 59, 2344-2353 (2012).
15. Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N. Engl. J. Med. 367, 1891-1900 (2012).
16. Roth EM, Diller P. Alirocumab for hyperlipidemia: physiology of PCSK9 inhibition, pharmacodynamics and Phase I and II clinical trial results of a PCSK9 monoclonal antibody. Future Cardiol. 10(2), 183-99 (2014).
17. Pordy R, Lecrops G, Bessac L, Sasiela WG, Ginsberg H. Alirocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9: therapeutic dosing in Phase 3 studies. J. Clin. Lipidol. 7, 279 (2013).
18. Roth EM, Taskinen MR, Ginsberg HN et al. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial. Int. J. Cardiol. 176(1), 55-61 (2014).
19. Conroy RM, Pyorala K, Fitzgerald AP et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur. Heart J. 24(11), 987-1003 (2003).
20. Bays HE, Neff D, Tomassini JE, Tershakovec AM. Ezetimibe: cholesterol lowering and beyond. Expert Rev. Cardiovasc. Ther. 6(4), 447-470 (2008).
21. Dubuc GA, Chamberland H, Wassef J et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 24, 1454-1459 (2004).